Abstract
Genetic engineering of T lymphocytes to confer new antitumor specificities is a fascinating approach that may help the successful clinical translation of adoptive immunotherapy strategies. The recognition of tumor-specific antigens may be obtained inducing the membrane expression of transgene encoded antitumor T cell receptors (TCR) or chimeric antigen receptors (CAR). Few but very informative clinical trials with TCR or CAR redirected T lymphocytes have been attempted in the last years, reporting important clinical results along with disappointing failures and important warnings. In this work, we will focus on TCR and CAR redirected T lymphocytes as adoptive immunotherapy for solid tumors. We will review the main topics of these strategies from the angle of clinical applications, discussing the main issues that emerged from early clinical trials and their impact on next study designs.
Keywords: Adoptive immunotherapy, solid tumors, transgenic CAR, transgenic TCR.
Current Gene Therapy
Title:Genetically Redirected T Lymphocytes for Adoptive Immunotherapy of Solid Tumors
Volume: 14 Issue: 1
Author(s): Valeria Leuci, Giulia Mesiano, Loretta Gammaitoni, Massimo Aglietta and Dario Sangiolo
Affiliation:
Keywords: Adoptive immunotherapy, solid tumors, transgenic CAR, transgenic TCR.
Abstract: Genetic engineering of T lymphocytes to confer new antitumor specificities is a fascinating approach that may help the successful clinical translation of adoptive immunotherapy strategies. The recognition of tumor-specific antigens may be obtained inducing the membrane expression of transgene encoded antitumor T cell receptors (TCR) or chimeric antigen receptors (CAR). Few but very informative clinical trials with TCR or CAR redirected T lymphocytes have been attempted in the last years, reporting important clinical results along with disappointing failures and important warnings. In this work, we will focus on TCR and CAR redirected T lymphocytes as adoptive immunotherapy for solid tumors. We will review the main topics of these strategies from the angle of clinical applications, discussing the main issues that emerged from early clinical trials and their impact on next study designs.
Export Options
About this article
Cite this article as:
Leuci Valeria, Mesiano Giulia, Gammaitoni Loretta, Aglietta Massimo and Sangiolo Dario, Genetically Redirected T Lymphocytes for Adoptive Immunotherapy of Solid Tumors, Current Gene Therapy 2014; 14 (1) . https://dx.doi.org/10.2174/1566523213666131223130353
DOI https://dx.doi.org/10.2174/1566523213666131223130353 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
N-Acetylcysteine and Other Preventive Measures for Contrast-Induced Nephropathy in the Intensive Care Unit
Current Medicinal Chemistry Pathogenesis and Management of Intradialytic Hypertension
Current Hypertension Reviews Editorial [Hot Topic:Toward Translational Research on VIP AND PACAP (Executive Editor: A. Arimura)]
Current Pharmaceutical Design Current Therapeutics, Their Problems and Thiol Metabolism as Potential Drug Targets in Leishmaniasis
Current Drug Metabolism Recent Highlights on Molecular Hybrids Potentially Useful in Central Nervous System Disorders
Mini-Reviews in Medicinal Chemistry Novel Atypical Antipsychotics: Metabolism and Therapeutic Drug Monitoring (TDM)
Current Drug Metabolism Metal Complexes, their Cellular Targets and Potential for Cancer Therapy
Current Pharmaceutical Design Development and Characterization of Cassia grandis and Bixa orellana Nanoformulations
Current Topics in Medicinal Chemistry Prodrug Strategies for Antihypertensives
Current Topics in Medicinal Chemistry Analgesia in PACU: Nonsteroidal Anti-Inflammatory Drugs
Current Drug Targets Turning Foes to Friends: Knocking Down Diabetes Associated SGLT2 Transporters and Sustaining Life
Current Diabetes Reviews Obesity, Metabolic Syndrome, Diabetes and Arterial Hypertension
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Extrahepatic Targets and Cellular Reactivity of Drug Metabolites
Current Medicinal Chemistry Past, Present and Future Strategies of Immunotherapy in Gynecological Malignancies
Current Molecular Medicine Acute Fulminant Hepatatis in Kidney Transplant Recipient After Repeated Sevoflurane Anesthesia - A Case Report and Literature Review
Current Drug Safety Contemporary Pharmacologic Management of Heart Failure with Reduced Ejection Fraction: A Review
Current Cardiology Reviews A2A Adenosine Receptor and its Modulators: Overview on a Druggable GPCR and on Structure-Activity Relationship Analysis and Binding Requirements of Agonists and Antagonists
Current Pharmaceutical Design L-Arginine Availability as a Pathological Mechanism in Essential Hypertension, Chronic Renal and Heart Failure
Vascular Disease Prevention (Discontinued) Scorpion Toxin Polyptides as Therapeutic Agents: An Overview
Protein & Peptide Letters Pharmacological Treatments for Cocaine Dependence: Is There Something New?
Current Pharmaceutical Design